Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) Other Non-Current Liabilities (2020 - 2026)

Cogent Biosciences' Other Non-Current Liabilities history spans 5 years, with the latest figure at $62000.0 for Q1 2026.

  • Quarterly Other Non-Current Liabilities rose 1140.0% to $62000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $62000.0 through Mar 2026, up 1140.0% year-over-year, with the annual reading at $33000.0 for FY2025, N/A changed from the prior year.
  • Other Non-Current Liabilities came in at $62000.0 for Q1 2026, up from $33000.0 in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $2.4 million in Q3 2025 to a low of $5000.0 in Q1 2025.
  • The 3-year median for Other Non-Current Liabilities is $881000.0 (2022), against an average of $1.1 million.
  • Year-over-year, Other Non-Current Liabilities plummeted 44.44% in 2022 and then skyrocketed 1140.0% in 2026.
  • Cogent Biosciences' Other Non-Current Liabilities stood at $1.7 million in 2022, then tumbled by 98.06% to $33000.0 in 2025, then skyrocketed by 87.88% to $62000.0 in 2026.
  • Per Business Quant, the three most recent readings for COGT's Other Non-Current Liabilities are $62000.0 (Q1 2026), $33000.0 (Q4 2025), and $2.4 million (Q3 2025).